Pfizer’s earnings seasons are ahead with $1 expected for the EPS and $16.67 billion revenue estimated.
Pfizer Inc. is a biopharmaceutical company with a global presence that relies on research as the basis for its operations. The company has multiple late-stage programs in its sustainable pipeline that can fuel its growth. Pfizer markets an array of vaccines and drugs, and its business consists of six units: Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines, and Internal Medicine.
So, with earnings ahead, look at the seasonals that are coming up for Pfizer to potentially time any entries or exits. The first half of May favours seasonal strength for Pfizer stock over the last 25 years, but that soon fades into the summer months.
Check out the details in the video above!
Major Trade Risks:
The major trade risk here is that earnings surprise significantly.
Remember, don’t just trade it, but Seasonax it!